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SESSION INFORMATION
Background/Purpose: The association of low titer anti-phospholipid antibodies (aPL) with
obstetric anti-phospholipid syndrome (APS) is increasingly acknowledged, even though some
studies have showed conflicting results. To raise further evidence on the relevance of low titer
aPL in pregnancy morbidity (PM), we retrospectively reviewed the clinical records of pregnant
women attending a joint obstetric/rheumatology clinic over the years 2009-2016.
Methods: Patients were included when positive in at least one criteria aPL assay, at any titer, in
two occasions minimum 12 weeks apart. Statistical analysis was performed using R package.
Results:  111 women (338 pregnancies) were identified. 51 women displayed low-titer aPL, with
160 pregnancies. 60 patients carried aPL at medium-high titers, with 178 pregnancies. 4 patients
(4%) had thrombotic APS, 27 (24%) obstetric APS, 7 (6%) thrombotic and obstetric APS, 15 (14%)
medium-high titer aPL and non criteria PM, 7 (6%) medium-high titer aPL and no PM, 18 (16%) low
titer aPL and non criteria PM and 15 (14%) low titer aPL and no PM. Low-titer aPL were significantly
associated with pregnancy complications (c =8.82, p=0.003). Considering 245 untreated
pregnancies, a significant difference in PM distribution was noted for low titer and medium-high
titer aPL (p=0.003, Table 1). Among patients with low titer aPL, treatment with low molecular
weight heparin [LMWH] + low-dose aspirin [LDASA] significantly improved pregnancy outcomes
(p<<0.001, odds ratio [OR]=0.07, 95% CI=0.007–0.300), leading to a 14.3-fold reduction of obstetric
complications. Hydroxychloroquine [HCQ]  was not associated with a significant improvement in
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complications. Hydroxychloroquine [HCQ]  was not associated with a significant improvement in
live birth rate (p=0.079). Among women with medium-high titer aPL, the standard therapeutic
approach with LMWH+LDASA resulted in a significant improvement of obstetric outcome
(p<<0.001, OR=0.20, 95% CI=0.100–0.400). HCQ treatment significantly improved obstetric
outcome, carrying a 3-fold increase in the live birth rate (p=0.025, OR=0.34, 95% CI=0.117–0.894).
Conclusion: According to our data, low titer aPL are significantly associated with aPL-associated
obstetric complications, with a lower prevalence of premature birth compared to medium-high
titer aPL. Treatment with LDASA+LMWH led to a higher increase of live birth rate in women with
low titer aPL compared to those with medium-high titer aPL. Additional treatment such as HCQ
were effective in women with medium-high titer aPL but not those with low titer aPL.         Table 1.
Obstetric outcomes (defined according to Miyakis et al, 2006) in 245 untreated pregnancies in
women with low titer and medium-high titer anti-phospholipid antibodies.      
 




Low titer aPL 57 (42%) 60 (45%) 16 (12%) 1 (1%) 134
Medium-high titer aPL 31 (28%) 59 (53%) 13 (12%) 8 (7%) 111
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